Abstract
Although clozapine is the treatment of choice for treatment-refractory schizophrenia, 30-40% of patients have an insufficient response, and others are unable to tolerate it. Evidence for any augmentation strategies is scarce. We aimed to determine whether cognitive behavioural therapy (CBT) is an effective treatment for clozapine-resistant schizophrenia. We did a pragmatic, parallel group, assessor-blinded, randomised controlled trial in community-based and inpatient mental health services in five sites in the UK. Patients with schizophrenia who were unable to tolerate clozapine, or whose symptoms did not respond to the drug, were randomly assigned 1:1 by use of randomised-permuted blocks of size four or six, stratified by centre, to either CBT plus treatment as usual or treatment as usual alone. Research assistants were masked to allocation to protect against rater bias and allegiance bias. The primary outcome was the Positive and Negative Syndrome Scale (PANSS) total score at 21 months, which provides a continuous measure of symptoms of schizophrenia; PANSS total was also assessed at the end of treatment (9 months). The primary analysis was by randomised treatment based on intention to treat, for all patients for whom data we...Continue Reading
Citations
Aug 17, 2018·The British Journal of Psychiatry : the Journal of Mental Science·Derek K TracySukhwinder S Shergill
Jan 31, 2019·Journal of Psychopharmacology·Elias WagnerAlkomiet Hasan
Feb 27, 2019·Health Technology Assessment : HTA·Anthony P MorrisonDavid Kingdon
Feb 14, 2019·Psychological Medicine·S JauharP J McKenna
Feb 23, 2020·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Elias WagnerAlkomiet Hasan
May 19, 2020·Schizophrenia Bulletin·Elias WagnerUNKNOWN TRRIP Working Group
Sep 12, 2020·BMJ Open·Gemma E ShieldsLinda M Davies
Sep 12, 2020·Psychology and Psychotherapy·Filippo VareseDouglas Turkington
Aug 20, 2019·Schizophrenia Bulletin·Stefania TogninUNKNOWN PSYSCAN Consortium
Feb 15, 2020·Indian Journal of Psychiatry·Ajit AvasthiSandeep Grover
Oct 2, 2020·BMJ Evidence-based Medicine·Sophie JuulJanus Christian Jakobsen
Nov 28, 2018·Irish Journal of Psychological Medicine·J Lally, F Gaughran
Mar 30, 2020·Schizophrenia Bulletin·David T TurnerMark van der Gaag
Apr 15, 2020·European Journal of Psychotraumatology·Rosie AdamsEmily Wood
Dec 6, 2018·BMC Psychiatry·Irene BighelliStefan Leucht
May 7, 2019·Frontiers in Psychiatry·Daniela PoleseAndrea de Bartolomeis
Oct 21, 2020·Journal of Mental Health·Aleksandar TodorovicDan Siskind
Dec 2, 2020·Medicina·Siân Lowri Griffiths, Max Birchwood
Jan 11, 2021·Acta Psychiatrica Scandinavica·Sameer JauharAllan H Young
Jan 18, 2021·Schizophrenia Research·Mattia CampanaElias Wagner
May 6, 2021·International Journal of Environmental Research and Public Health·Wei YuBinggen Zhu
Jul 11, 2020·The Lancet. Psychiatry·Anthony P MorrisonUNKNOWN MAPS group
Jul 10, 2021·BMC Psychiatry·Norika Mitsunaga-Ohmuro, Noriyuki Ohmuro
Nov 21, 2021·BMC Psychiatry·Robert O CotesTristan Gorrindo